NR4A2 and endothelial dysfunction: Additionally, treatment with the therapeutic pravastatin, a drug currently in trial to prevent preeclampsia, had no effect on NR4A2 expression under endothelial dysfunction, suggesting that pravastatin treatment does not affect regulation of this transcription factor.